Art. -Nr.: HY-13962

SGI-1027

19 Cited Publications

Kundenbewertung

Based on 19 publication(s) in Google Scholar

SGI-1027 is a DNA methyltransferase (DNMT) inhibitor, with IC₅₀s of 7.5 μM, 8 μM, and 12.5 μM for DNMT3B, DNMT3A, and DNMT1 with poly(dI-dC) as substrate.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.79%
CAS. Nr.: 1020149-73-8
Formel: C₂₇H₂₃N₇O
Molecular Weight:461.52

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

SGI-1027 Chemical Structure

CAS. Nr.: 1020149-73-8

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
Chemical Information
Publications (19)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Protokoll
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

SGI-1027 is a DNA methyltransferase (DNMT) inhibitor, with IC₅₀s of 7.5 μM, 8 μM, and 12.5 μM for DNMT3B, DNMT3A, and DNMT1 with poly(dI-dC) as substrate.

IC₅₀ & Target^[1]

DNMT3B

7.5 μM (IC₅₀)

DNMT3A

8 μM (IC₅₀)

DNMT1

12.5 μM (IC₅₀)

Alle DNA Methyltransferase Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	8.9 μM Compound: SGI-1027	Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay	[PMID: 36029561]
DU-145	IC₅₀	3.4 μM Compound: SGI-1027	Antiproliferative activity against human DU-145 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay Antiproliferative activity against human DU-145 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay	[PMID: 36029561]
HCT-116	EC₅₀	>10 μM Compound: SGI1027	Antiproliferative activity against human HCT116 cells after 2 to 4 days by ATPlite 1step luminescence assay Antiproliferative activity against human HCT116 cells after 2 to 4 days by ATPlite 1step luminescence assay	[PMID: 26220519]
HCT-116	IC₅₀	0.9 μM Compound: SGI-1027	Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay	[PMID: 36029561]
HCT-116	IC₅₀	3.2 μM Compound: SGI-1027	Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability measured after 72 hrs by Alamar blue assay Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability measured after 72 hrs by Alamar blue assay	[PMID: 34333394]
K562	IC₅₀	0.6 μM Compound: SGI-1027	Antiproliferative activity against human K562 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay Antiproliferative activity against human K562 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay	[PMID: 36029561]
K562	IC₅₀	1.16 μM Compound: SGI-1027	Antiproliferative activity against human K562 cells after 72 hrs by MTT assay Antiproliferative activity against human K562 cells after 72 hrs by MTT assay	[PMID: 28419930]
KARPAS-299	EC₅₀	1.8 μM Compound: SGI1027	Antiproliferative activity against human KARPAS299 cells after 2 to 4 days by ATPlite 1step luminescence assay Antiproliferative activity against human KARPAS299 cells after 2 to 4 days by ATPlite 1step luminescence assay	[PMID: 26220519]
KG-1	EC₅₀	4.4 μM Compound: SGI1027	Antiproliferative activity against human KG1 cells after 2 to 4 days by ATPlite 1step luminescence assay Antiproliferative activity against human KG1 cells after 2 to 4 days by ATPlite 1step luminescence assay	[PMID: 26220519]
KG-1	IC₅₀	1.7 μM Compound: SGI-1027	Cytotoxicity against human KG-1 cells Cytotoxicity against human KG-1 cells	[PMID: 34655985]
MDA-MB-231	IC₅₀	1.7 μM Compound: SGI-1027	Cytotoxicity against human MDA-MB-231 cells Cytotoxicity against human MDA-MB-231 cells	[PMID: 34655985]
MDA-MB-231	IC₅₀	4.8 μM Compound: 1, SGI-1027	Cytotoxicity against human MDA-MB-231 cells after 48 hrs by trypan blue exclusion assay Cytotoxicity against human MDA-MB-231 cells after 48 hrs by trypan blue exclusion assay	[PMID: 24387159]
PBMC	IC₅₀	2 μM Compound: SGI-1027	Cytotoxicity activity against human PBMC cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay Cytotoxicity activity against human PBMC cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay	[PMID: 36029561]
PBMC	IC₅₀	23.8 μM Compound: 1, SGI-1027	Cytotoxicity against human PBMC after 48 hrs by trypan blue exclusion assay Cytotoxicity against human PBMC after 48 hrs by trypan blue exclusion assay	[PMID: 24387159]
PC-3	IC₅₀	1.7 μM Compound: SGI-1027	Antiproliferative activity against human PC-3 cells Antiproliferative activity against human PC-3 cells	[PMID: 34655985]
PC-3	IC₅₀	6.5 μM Compound: 1, SGI-1027	Cytotoxicity against human PC3 cells after 48 hrs by trypan blue exclusion assay Cytotoxicity against human PC3 cells after 48 hrs by trypan blue exclusion assay	[PMID: 24387159]
Raji	IC₅₀	1.7 μM Compound: SGI-1027	Cytotoxicity against human Raji cells Cytotoxicity against human Raji cells	[PMID: 34655985]
Raji	IC₅₀	9.1 μM Compound: 1, SGI-1027	Cytotoxicity against human Raji cells after 48 hrs by trypan blue exclusion assay Cytotoxicity against human Raji cells after 48 hrs by trypan blue exclusion assay	[PMID: 24387159]
Sf9	IC₅₀	6 μM Compound: 7, SGI1027	Inhibition of His6-tagged human recombinant DNMT1 expressed in insect Sf9 cells assessed as reduction in DNA methyltransferase activity using 5'-biotinylated 45-bp unmethylated or hemimethylated oligonucleotide substrates and [3H]-AdoMet by liquid scintil Inhibition of His6-tagged human recombinant DNMT1 expressed in insect Sf9 cells assessed as reduction in DNA methyltransferase activity using 5'-biotinylated 45-bp unmethylated or hemimethylated oligonucleotide substrates and [3H]-AdoMet by liquid scintil	[PMID: 25406944]
Sf9	IC₅₀	7.5 μM Compound: 7, SGI1027	Inhibition of His6-tagged human recombinant DNMT3b expressed in insect Sf9 cells assessed as reduction in DNA methyltransferase activity using 5'-biotinylated 45-bp unmethylated or hemimethylated oligonucleotide substrates and [3H]-AdoMet by liquid scinti Inhibition of His6-tagged human recombinant DNMT3b expressed in insect Sf9 cells assessed as reduction in DNA methyltransferase activity using 5'-biotinylated 45-bp unmethylated or hemimethylated oligonucleotide substrates and [3H]-AdoMet by liquid scinti	[PMID: 25406944]
Sf9	IC₅₀	8 μM Compound: 7, SGI1027	Inhibition of His6-tagged human recombinant DNMT3a expressed in insect Sf9 cells assessed as reduction in DNA methyltransferase activity using 5'-biotinylated 45-bp unmethylated or hemimethylated oligonucleotide substrates and [3H]-AdoMet by liquid scinti Inhibition of His6-tagged human recombinant DNMT3a expressed in insect Sf9 cells assessed as reduction in DNA methyltransferase activity using 5'-biotinylated 45-bp unmethylated or hemimethylated oligonucleotide substrates and [3H]-AdoMet by liquid scinti	[PMID: 25406944]
THP-1	IC₅₀	0.7 μM Compound: SGI-1027	Antiproliferative activity against human THP-1 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay Antiproliferative activity against human THP-1 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay	[PMID: 36029561]
U-937	IC₅₀	0.7 μM Compound: SGI-1027	Antiproliferative activity against human U-937 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay Antiproliferative activity against human U-937 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay	[PMID: 36029561]
U-937	IC₅₀	1.56 μM Compound: SGI-1027	Antiproliferative activity against human U937 cells after 72 hrs by MTT assay Antiproliferative activity against human U937 cells after 72 hrs by MTT assay	[PMID: 28419930]
U-937	IC₅₀	1.7 μM Compound: 1, SGI-1027	Cytotoxicity against human U937 cells after 48 hrs by trypan blue exclusion assay Cytotoxicity against human U937 cells after 48 hrs by trypan blue exclusion assay	[PMID: 24387159]
U-937	IC₅₀	1.7 μM Compound: SGI-1027	Cytotoxicity against human U-937 cells Cytotoxicity against human U-937 cells	[PMID: 34655985]

In Vitro

SGI-1027 is a DNMT inhibitor, with IC₅₀s of 7.5 μM, 8 μM, and 12.5 μM for DNMT3B, DNMT3A, and DNMT1 with poly(dI-dC) as substrate. SGI-1027 shows an IC₅₀ of 6 μM for DNMT1 (hemimethylated DNA). SGI-1027 (1, 2.5, or 5 μM) causes selective degradation of DNMT1 in several human cancer cell lines, but shows little or no cytotoxic effect on rat hepatoma cells, and does not induce apoptosis in rat hepatoma cells^[1]. SGI-1027 shows an EC₅₀ of 0.9 μM for hDNMT3A, and causes cytotoxicity on KG-1 cells, with an EC₅₀ of 4.4 μM^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS. Nr. 1020149-73-8
Appearance Solid
Molecular Weight 461.52
Formel C₂₇H₂₃N₇O
Color Light yellow to yellow
SMILES

O=C(NC1=CC=C(NC2=NC(N)=NC(C)=C2)C=C1)C3=CC=C(NC4=CC=NC5=CC=CC=C45)C=C3
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (19)

All WBCell Proliferation/Viability AssayCell Imaging/StainingFlow CytometryIP

Sort by:

Journal Impact Factor

Nat Commun

Selective inhibition of cancer cell self-renewal through a Quisinostat-histone H1.0 axis. [Abstract]

2020 Apr 14;11(1):1792. PMID: 32286289
Adv Sci (Weinh)

Microcystin-LR Triggers Renal Tubular Ferroptosis Through Epigenetic Repression of GPX4: Implications for Environmental Nephrotoxicity. [Abstract]

2025 Nov 30:e14349. PMID: 41319283

SGI-1027 purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Nov 30:e14349. [Abstract]

Western blot analysis of GPX4, E-cad, α-SMA, and Col1α expression in HK2 cells treated with MC-LR with or without SGI-1027 (10 µM) for 48 h.

SGI-1027 purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Nov 30:e14349. [Abstract]

Representative images of C11-BODIPY and TUNEL staining in HK2 cells treated with MC-LR in the presence or absence of SGI-1027 (10 μM) for 48 h.

SGI-1027 purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Nov 30:e14349. [Abstract]

ChIP assay of renal tissues from Ctrl and MC-LR-exposed mice with or without SGI-1027 (2.5 mg/kg, i.p.) treatment.
Adv Sci (Weinh)

Methuosis Inducer SGI-1027 Cooperates with Everolimus to Promote Apoptosis and Pyroptosis by Triggering Lysosomal Membrane Permeability in Renal Cancer. [Abstract]

2024 Aug 9:e2404693. PMID: 39119834

SGI-1027 purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2024 Aug 9:e2404693. [Abstract]

CCK-8 assay for detecting the cell proliferation of 786-O and A-498 cells treated with DMSO (control), 5 μM Everolimus, 1.5 μM SGI-1027, or their combination for indicated time.

SGI-1027 purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2024 Aug 9:e2404693. [Abstract]

The synergistic effect of SGI-1027 (1.5 μM) and everolimus on the cell cycle of renal cancer cells.
Research (Wash D C)

DNA Methylation-Mediated GPX4 Transcriptional Repression and Osteoblast Ferroptosis Promote Titanium Particle-Induced Osteolysis. [Abstract]

2024 Aug 19:7:0457. PMID: 39161535
Cell Rep Med

HIF-activated priming of TRAIL-induced cell death determines epigenetic vulnerability in kidney cancer. [Abstract]

2026 Feb 18:102630. PMID: 41713410
Pharmacol Res

Epigenetic regulation of the DNMT1/MT1G/KLF4/CA9 axis synergises the anticancer effects of sorafenib in hepatocellular carcinoma. [Abstract]

2022 Jun;180:106244. PMID: 35550167
Cancer Lett

Targeting MKK3/c-Myc interaction to overcome osimertinib acquired resistance in EGFR mutant lung cancer. [Abstract]

2025 Aug 29:633:218010. PMID: 40886822
Proc Natl Acad Sci U S A

MGMT-activated DUB3 stabilizes MCL1 and drives chemoresistance in ovarian cancer. [Abstract]

2019 Feb 19;116(8):2961-2966. PMID: 30718431
Acta Pharmacol Sin

DNMT inhibition epigenetically restores the cGAS-STING pathway and activates RIG-I/MDA5-MAVS to enhance antitumor immunity. [Abstract]

2025 Aug 19. PMID: 40830678
Free Radic Biol Med

Cannabidiol mitigates radiation-induced intestine ferroptosis via facilitating the heterodimerization of RUNX3 with CBFβ thereby promoting transactivation of GPX4. [Abstract]

2024 Jun 1:S0891-5849(24)00506-9. PMID: 38830513
Aging Cell

Inhibition of DNA methyltransferase aberrations reinstates antioxidant aging suppressors and ameliorates renal aging. [Abstract]

2022 Jan;21(1):e13526. PMID: 34874096
Ecotoxicol Environ Saf

Prenatal BPA exposure disrupts androgen synthesis in testicular Leydig cells via epigenetic modifications of steroidogenic factor 1. [Abstract]

2025 Nov 15:307:119409. PMID: 41252971
Chem Biol Interact

2026 May 27:112177. PMID: 42208724
Commun Biol

A genome-scale CRISPR Cas9 dropout screen identifies synthetically lethal targets in SRC-3 inhibited cancer cells. [Abstract]

2021 Mar 25;4(1):399. PMID: 33767353
Int J Mol Sci

Stalling the Enemy: Targeting Nsp13 for Next-Generation SARS-CoV-2 Antivirals. [Abstract]

2026 Mar 11;27(6):2587. PMID: 41898448
Eur J Pharmacol

Longikaurin A induces ferroptosis and inhibits glioblastoma progression through DNA methylation - Mediated GPX4 suppression. [Abstract]

2024 Dec 5:984:177061. PMID: 39426467
iScience

2025 Dec 4.
Research Square Preprint

2024 May 7.
bioRxiv

Quinoline-based compounds can inhibit diverse enzymes that act on DNA. [Abstract]

2024 Apr 3:2024.04.03.587980. PMID: 38617249

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 25 mg/mL (54.17 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.1668 mL

10.8338 mL

21.6675 mL

5 mM

0.4334 mL

2.1668 mL

4.3335 mL

10 mM

0.2167 mL

1.0834 mL

2.1668 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: 2.5 mg/mL (5.42 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: 2.5 mg/mL (5.42 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (5.42 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protokoll

Kinase Assay^[1]

To determine the nature of inhibition of DNMTase activity by SGI-1027, DNMT1 enzyme activity is measured in presence of a fixed concentration of SGI-1027 (0, 2.5, 5, and 10 μM) while one of the two (Ado-Met or DNA) is varied in a particular reaction mixture. At a fixed concentration of DNA (500 ng) varying concentrations of Ado-Met used are from 25-500 nM, respectively. Similarly, final DNA concentrations are varied from (25-500 ng) at 75 nM Ado-Met^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Assay^[1]

Rat hepatoma H4IIE cells are grown in DMEM supplemented with fetal bovine serum (10%) and calf serum (10%). Cells are seeded into 96-well plates and after 48 h exposed to SGI-1027 at concentrations ranging from 0 to 300 µM. The solubility is determined by Nephalometry techniques immediately after dosing and before harvesting the cells at 24 h. Following the exposure period, the cells or their supernatant (culture medium) are analyzed for changes in cell proliferation (propidium iodide), membrane leakage (α-GST), mitochondrial function [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide and cellular ATP], oxidative stress (intracellular GSH and 8-isoprostane), and apoptosis (caspase-3). The half-maximal toxic concentration (TC₅₀) is determined from the dose-response curves^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (276 KB)
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Korean - KR (396 KB)
- Portuguese - PT (396 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Datta J, et al. A new class of quinoline-based DNA hypomethylating agents reactivates tumor suppressor genes by blocking DNA methyltransferase 1 activity and inducing its degradation. Cancer Res. 2009 May 15;69(10):4277-85. [Content Brief]

[2]. Rilova E, et al. Design, synthesis and biological evaluation of 4-amino-N- (4-aminophenyl)benzamide analogues of quinoline-based SGI-1027 as inhibitors of DNA methylation. ChemMedChem. 2014 Mar;9(3):590-601. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.1668 mL	10.8338 mL	21.6675 mL	54.1688 mL
	5 mM	0.4334 mL	2.1668 mL	4.3335 mL	10.8338 mL
	10 mM	0.2167 mL	1.0834 mL	2.1668 mL	5.4169 mL
	15 mM	0.1445 mL	0.7223 mL	1.4445 mL	3.6113 mL
	20 mM	0.1083 mL	0.5417 mL	1.0834 mL	2.7084 mL
	25 mM	0.0867 mL	0.4334 mL	0.8667 mL	2.1668 mL
	30 mM	0.0722 mL	0.3611 mL	0.7223 mL	1.8056 mL
	40 mM	0.0542 mL	0.2708 mL	0.5417 mL	1.3542 mL
	50 mM	0.0433 mL	0.2167 mL	0.4334 mL	1.0834 mL

Keywords

SGI-1027

19 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

SGI-1027

Apoptosis Compound Library

Epigenetics Compound Library

Immunology/Inflammation Compound Library

Anti-Cancer Compound Library

Reprogramming Compound Library

Anti-Blood Cancer Compound Library

Transcription Factor-Targeted Library

Cell Death Library

Anti-Hematopathy Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

Epigenetics Compound Library Mini

MCE Bioactive Compound Library

Bioactive Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

Methylation Compound Library

High-Throughput Bioactive Compound Library

Anti-Rheumatic Arthritis Compound Library

Posttranslational Modification Library

Publications Citing Use of MedChemExpress (MCE) SGI-1027

Alle DNA Methyltransferase Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (19)

Lösungsmittel & Löslichkeit

Protokoll

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

SGI-1027

Apoptosis Compound Library

Epigenetics Compound Library

Immunology/Inflammation Compound Library

Anti-Cancer Compound Library

Reprogramming Compound Library

Anti-Blood Cancer Compound Library

Transcription Factor-Targeted Library

Cell Death Library

Anti-Hematopathy Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

Epigenetics Compound Library Mini

MCE Bioactive Compound Library

Bioactive Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

Methylation Compound Library

High-Throughput Bioactive Compound Library

Anti-Rheumatic Arthritis Compound Library

Posttranslational Modification Library

Publications Citing Use of MedChemExpress (MCE) SGI-1027

Alle DNA Methyltransferase Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (19)

Lösungsmittel & Löslichkeit

Protokoll

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

SGI-1027 Related Classifications

HY-13962 Related Classifications